First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced that the final patient has been dosed in the Phase 2 SPAN clinical trial. The trial is investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. Topline..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing treatments for central nervous system diseases, provided clinical updates for its investigational programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at their recent R&D Day. The company discussed the results of comprehensive data analysis for TSHA-120, addressing feedback from the U.S..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms